Published in:
Open Access
01-12-2022 | Anaphylaxis | Case report
Two cases of circulatory collapse due to suspected remimazolam anaphylaxis
Authors:
Satoshi Uchida, Daiki Takekawa, Masato Kitayama, Kazuyoshi Hirota
Published in:
JA Clinical Reports
|
Issue 1/2022
Login to get access
Abstract
Background
Remimazolam was approved in Japan in January 2020. We report two cases of circulatory collapse due to suspected remimazolam anaphylaxis during anesthetic induction.
Case presentation
Case 1: A 74-year-old male was scheduled for debridement and skin grafting for a severe burn injury. We induced anesthesia with 4 mg of remimazolam and 20 mg of ketamine. The patient subsequently developed treatment-resistant severe hypotension.
Case 2: A 59-year-old male was scheduled for laparoscopic-assisted sigmoid colectomy. We induced anesthesia with 9 mg of remimazolam. Within a few minutes, the patient developed treatment-resistant severe hypotension.
As serum tryptase was elevated in both cases and only intravenous administration of adrenaline was effective, we considered the circulatory collapse might be due to anaphylaxis.
Conclusion
We experienced two cases of circulatory collapse due to suspected remimazolam anaphylaxis during anesthetic induction. The prevalence of remimazolam anaphylaxis is not yet known, and further research is needed.